Torrent Pharmaceuticals Limited (500420) Fair Value & Analysis
Healthcare · IN · Market cap ₹388B
Fair value as of: Aug 14, 2026
From 24 valuation models · updated today
Share price −1.9% over the past month.
A solid business, but screening 11% overvalued on our models.
What matters now
- The model range is unusually wide (₹1,984 to ₹7,472). The outcome hinges heavily on assumptions, so read the point estimate with caution.
- Our model range runs from ₹1,984 (bear) to ₹7,472 (bull), base ₹4,360. The closer the price sits to the lower half, the larger the margin of safety.
- Quality 53/100 (solid quality) with medium evidence: read the verdict with care.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 14, 2026.
How to read this chart
60‑month range ₹1,177 – ₹5,103 · fair‑value band ₹1,984 – ₹7,472 · the ₹4,876 price screens above the ₹4,360 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 14, 2026.
Analysis
Torrent Pharmaceuticals Limited (500420) currently trades at ₹4,876, while our model-based Fair Value estimate is ₹4,360, implying the stock looks roughly 10.6% overvalued today. The Quality Score stands at 53/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Net debt stands at ₹137B. The stock trades on a trailing P/E of 37.8 (as of Aug 14, 2026). Fundamentals as of Aug 14, 2026
Our scenario range runs from ₹1,984 (bear case) to ₹7,472 (bull case); at ₹4,876, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 7% below its 52-week high and 41% above its 52-week low. For context, the median of 10 Healthcare peers we cover trades at -14% fair-value upside, at -11%, 500420 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 24 models by family
Widest divergence: DCF Models (₹5,708) versus Asset-Based (₹706.85). Highest evidence: Growth DCF (80).
Notify me when 500420 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
Figures from reported company fundamentals · as of Aug 14, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 52 · Market factors (momentum, volatility) 75
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Torrent Pharmaceuticals Limited engages in the research, development, manufacturing, and marketing of generic pharmaceutical formulations in India and internationally.
Full company description
Torrent Pharmaceuticals Limited engages in the research, development, manufacturing, and marketing of generic pharmaceutical formulations in India and internationally. The company offers products in various therapeutic areas, including cardiovascular, central nervous system, gastrointestinal, diabetology, anti-infective, pain management, nephrology, oncology, gynecology, pediatric, wound care, and nutraceuticals. It also provides contract manufacturing services. The company was formerly known as Trinity Laboratories and changed its name to Torrent Pharmaceuticals Limited in 1971. The company was founded in 1959 and is based in Ahmedabad, India. Torrent Pharmaceuticals Limited is a subsidiary of Torrent Private Limited.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Torrent Pharmaceuticals Limited reported revenue of ₹138B in FY2025 versus ₹85.1B in FY2021, a compound +12.8%/yr. Reported net income was ₹21.6B in FY2025, compounding +29.2%/yr from FY2021.
500420 screens 11% overvalued. Compare with GlaxoSmithKline Pharmaceuticals Limited →
Peer Group
Pharmaceuticals · 25 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Pharmaceuticals median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Pharmaceuticals stocks, each showing price versus our Fair Value estimate (as of Aug 14, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| GlaxoSmithKline Pharmaceuticals Limited 500660 | ₹2,620 | ₹1,452 | -45% |
| Caregen Co 214370 | 64,400 KRW | 7,277 KRW | -89% |
| ST Pharm Co 237690 | 107,000 KRW | 50,110 KRW | -53% |
| Oscotec Inc 039200 | 38,800 KRW | 33,210 KRW | -14% |
| DongKook Pharmaceutical Co 086450 | 21,600 KRW | 31,283 KRW | +45% |
| Kolon Life Science Inc 102940 | 17,460 KRW | 37,129 KRW | +113% |
| Huons Global Co 084110 | 25,100 KRW | 58,482 KRW | +133% |
| BINEX Co 053030 | 7,300 KRW | 1,844 KRW | -75% |
| Anterogen.Co.,Ltd., a bio-venture company, 065660 | 15,520 KRW | 4,741 KRW | -69% |
| Kyung Dong Pharmaceutical Co 011040 | 5,180 KRW | 6,165 KRW | +19% |
Compare Torrent Pharmaceuticals Limited with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Torrent Pharmaceuticals Limited (500420) overvalued or undervalued?
What is the fair value of 500420?
What is the quality score of 500420?
What is the net profit margin of 500420?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Torrent Pharmaceuticals Limited and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.